On April 22, Amgen Inc. reported first-quarter profit that beat Wall Street expectations, which the company attributed to an increase in demand, and price, for their drugs. Amgen reported that earnings per share grew 33% to $2.48. Adjusted operating income increased 32% to $2,449 million. Total revenues increased 11% to $5,033million.

First quarter 2015 product sales performance

  • Neulasta(pegfilgrastim) sales increased 4% year-over-year driven primarily by price.
  • NEUPOGEN (filgrastim) sales decreased 15% year-over-year driven primarily by the impact of competition in the United States.
  • ENBRELsales increased 13% year-over-year driven by price.
  • XGEVA sales increased 22%year-over-year driven by higher unit demand.
  • Proliasales increased 39%year-over-year driven by higher unit demand.
  • EPOGEN sales increased 16%year-over-year due primarily to price and, to a lesser extent, higher unit demand.
  • Aranesp(darbepoetin alfa) sales increased 4% year-over-year driven by higher unit demand in international markets.
  • Sensipar/Mimpara sales increased 24% year-over-year driven by higher unit demand, favorable changes in inventory levels, and price.
  • Nplate (romiplostim) sales increased 12% year-over-year driven by higher unit demand.
  • Vectibix(panitumumab) sales increased 18% year-over-year driven by higher unit demand.
  • Kyprolis(carfilzomib) sales increased 59% year-over-year driven by higher unit demand.